Vectura recovery under way

Vectura recovery under way

Last year is fading from memory for pharma group Vectura (VEC). Revenues from top-selling drug Flutiform have returned to growth, partner Hikma (HIK) has restarted third-phase clinical trials after a new unbranded asthma medicine was rejected by the US Food and Drug Administration (FDA), and the integration of SkyePharma has reached its final stage.

To continue reading, subscribe today

and enjoy unlimited access to the following:

  • Tips of the Week
  • Funds coverage
  • Weekly features on big investment themes
  • Trading ideas
  • Comprehensive companies coverage
  • Economic analysis
Subscribe to Investors Chronicle

Subscribe today

Full access for just £3.37 a week:

• Tips and recommendations - to beat the market 
• Portfolio clinic & Mr Bearbull - build a well-planned portfolio 
• Expert tools - track and manage investments effortlessly
• Plus free delivery to your home or office

Subscribe Now